Gilead’s Yescarta Growth Continues, But Momentum Slowed
Yescarta brought in $75m in the third quarter, up 10% sequentially, and well above the $20m tallied by competitor Kymriah. Gilead also saw continued HIV sales growth, with HCV sales in line with expectations.
You may also be interested in...
Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.